Renalytix Plc (LON:RENX – Get Free Report)’s stock price traded up 1.8% on Thursday. The stock traded as high as GBX 5.90 and last traded at GBX 5.56. 2,739,277 shares changed hands during trading, an increase of 154% from the average daily volume of 1,079,704 shares. The stock had previously closed at GBX 5.47.
Renalytix Trading Up 2.4%
The firm has a market capitalization of £39.83 million, a P/E ratio of -1.49 and a beta of 1.71. The stock’s 50-day simple moving average is GBX 5.24 and its two-hundred day simple moving average is GBX 3.30. The company has a debt-to-equity ratio of -483.33, a current ratio of 1.57 and a quick ratio of 2.42.
Insider Activity at Renalytix
In other news, insider Christopher H. B. Mills sold 1,166,667 shares of the firm’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of GBX 6, for a total transaction of £70,000.02. 5.99% of the stock is owned by insiders.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Further Reading
- Five stocks we like better than Renalytix
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
